Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
1 "Urinary bladder neoplasms"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Article
The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone
Sun Ok Song, Kwang Joon Kim, Byung-Wan Lee, Eun Seok Kang, Bong Soo Cha, Hyun Chul Lee
Diabetes Metab J. 2012;36(5):371-378.   Published online October 18, 2012
DOI: https://doi.org/10.4093/dmj.2012.36.5.371
  • 5,330 View
  • 34 Download
  • 30 Crossref
AbstractAbstract PDFPubReader   
Background

There is growing concern regarding the increased incidence of bladder cancer in diabetic patients using pioglitazone. This study aimed to investigate the association between bladder cancer and the use of pioglitazone in Korean diabetics.

Methods

This retrospective, matched case-control study included a case group (n=329) of diabetic patients with bladder cancer who presented at the Severance Hospital from November 2005 to June 2011. The control group consisted of patients without bladder cancer (1:2 ratio matching for sex and age, n=658) who were listed on the Severance Hospital diabetes registry.

Results

The percentage of subjects who had ever used pioglitazone was significantly lower in the case group than in the control group (6.4% vs. 15.0%, P<0.001). Multivariate conditional logistic analysis revealed that independent factors affecting bladder cancer were smoking (odds ratio [OR], 11.64; 95% confidence interval [CI], 6.56 to 20.66; P<0.001), coexisting cancer (OR, 6.11; 95% CI, 2.25 to 16.63; P<0.001), and hemoglobin levels (OR, 0.78; 95% CI, 0.69 to 0.88; P<0.001). The OR of the history of pioglitazone use was 2.09 and was not significantly different between the two groups (95% CI, 0.26 to 16.81; P=0.488).

Conclusion

A relationship between pioglitazone use and incidence of bladder cancer was not observed in Korean diabetic patients. This suggests that the risk for bladder cancer in Korean diabetic subjects treated with pioglitazone might be different from that of Caucasian populations. Large-scale, well-designed and multi-center studies are needed to further evaluate this relationship.

Citations

Citations to this article as recorded by  
  • Cancer biology in diabetes update: Focusing on antidiabetic drugs
    Emi Kawakita, Keizo Kanasaki
    Journal of Diabetes Investigation.2024; 15(5): 525.     CrossRef
  • Pioglitazone, Bladder Cancer, and the Presumption of Innocence
    Georgios S. Papaetis
    Current Drug Safety.2022; 17(4): 294.     CrossRef
  • A systematic review of observational studies of the association between pioglitazone use and bladder cancer
    E. Ripamonti, L. Azoulay, M. Abrahamowicz, R.W. Platt, S. Suissa
    Diabetic Medicine.2019; 36(1): 22.     CrossRef
  • Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type‐2 diabetes
    Elizabeth M. Garry, John B. Buse, Mugdha Gokhale, Jennifer L. Lund, Matthew E. Nielsen, Virginia Pate, Til Stürmer
    Diabetes, Obesity and Metabolism.2019; 21(9): 2096.     CrossRef
  • Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies
    Juha Mehtälä, Houssem Khanfir, Dimitri Bennett, Yizhou Ye, Pasi Korhonen, Fabian Hoti
    Diabetology International.2019; 10(1): 24.     CrossRef
  • Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
    Melissa A. Davidson, Donald R. Mattison, Laurent Azoulay, Daniel Krewski
    Critical Reviews in Toxicology.2018; 48(1): 52.     CrossRef
  • An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug’s effect on cardiovascular disease and non-alcoholic steatohepatitis
    Mayer B. Davidson, Deyu Pan
    Diabetes Research and Clinical Practice.2018; 135: 102.     CrossRef
  • Pioglitazone and risk of bladder cancer in type 2 diabetes mellitus patients: A systematic literature review and meta-analysis of observational studies using real-world data
    Mohammad Adil, Rashid Ali Khan, Pinaki Ghosh, Shiva Kumar Venkata, Amit Dattatraya Kandhare, Manju Sharma
    Clinical Epidemiology and Global Health.2018; 6(2): 61.     CrossRef
  • Pioglitazone and bladder cancer risk: a systematic review and meta‐analysis
    Huilin Tang, Weilong Shi, Shuangshuang Fu, Tiansheng Wang, Suodi Zhai, Yiqing Song, Jiali Han
    Cancer Medicine.2018; 7(4): 1070.     CrossRef
  • Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes
    Hua Qu, Yi Zheng, Yuren Wang, Rui Zhang, Xiongzhong Ruan, Gangyi Yang, Zhenqi Liu, Hongting Zheng
    Scientific Reports.2017;[Epub]     CrossRef
  • Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
    Elena Filipova, Katya Uzunova, Krassimir Kalinov, Toni Vekov
    Diabetes Therapy.2017; 8(4): 705.     CrossRef
  • Pioglitazone does not increase the risk of type II diabetes in patients with bladder cancer: A retrospective study
    YOUHONG DONG, ANPING WANG
    Oncology Letters.2016; 12(1): 89.     CrossRef
  • Ten‐year observational follow‐up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes
    E. Erdmann, S. Harding, H. Lam, A. Perez
    Diabetes, Obesity and Metabolism.2016; 18(3): 266.     CrossRef
  • Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence
    Mayer B. Davidson
    Journal of Diabetes and its Complications.2016; 30(6): 981.     CrossRef
  • The current role of thiazolidinediones in diabetes management
    Christos V. Rizos, Anastazia Kei, Moses S. Elisaf
    Archives of Toxicology.2016; 90(8): 1861.     CrossRef
  • Development of vascular complications and bladder carcinoma in diabetics using pioglitazone: A five-year Indian review
    Saarwaani Vallabhajosyula, Shashaank Vallabhajosyula, Saraschandra Vallabhajosyula, Suma Nair, Asha Kamath, Karthik N. Rao
    Medical Journal Armed Forces India.2016; 72(3): 253.     CrossRef
  • Baseline glycemic status and mortality in 241,499 Korean metropolitan subjects: A Kangbuk Samsung Health Study
    Eun-Jung Rhee, Se Eun Park, Yoosoo Chang, Seungho Ryu, Won-Young Lee
    Metabolism.2016; 65(2): 68.     CrossRef
  • Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes
    Eugene Han, Suk-Yong Jang, Gyuri Kim, Yong-ho Lee, Eun Yeong Choe, Chung Mo Nam, Eun Seok Kang
    Medicine.2016; 95(6): e2786.     CrossRef
  • Polemics of pioglitazone: an appraisal in 2015
    Awadhesh Kumar Singh
    Expert Review of Endocrinology & Metabolism.2015; 10(4): 447.     CrossRef
  • Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis
    Daniel Levin, Samira Bell, Reijo Sund, Sirpa A. Hartikainen, Jaakko Tuomilehto, Eero Pukkala, Ilmo Keskimäki, Ellena Badrick, Andrew G. Renehan, Iain E. Buchan, Samantha L. Bowker, Jasjeet K. Minhas-Sandhu, Zafar Zafari, Carlo Marra, Jeffrey A. Johnson, B
    Diabetologia.2015; 58(3): 493.     CrossRef
  • Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta‐analysis
    Richard M. Turner, Chun S. Kwok, Chen Chen‐Turner, Chinedu A. Maduakor, Sonal Singh, Yoon K. Loke
    British Journal of Clinical Pharmacology.2014; 78(2): 258.     CrossRef
  • A Review on Thiazolidinediones and Bladder Cancer in Human Studies
    Chin-Hsiao Tseng
    Journal of Environmental Science and Health, Part C.2014; 32(1): 1.     CrossRef
  • Physiological Functions of Peroxisome Proliferator-Activated Receptor β
    Jaap G. Neels, Paul A. Grimaldi
    Physiological Reviews.2014; 94(3): 795.     CrossRef
  • Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study
    Sang-Man Jin, Sun Ok Song, Chang Hee Jung, Jin-Sun Chang, Sunghwan Suh, Seung Min Kang, Inkyung Jung, Cheol-Young Park, Jae Hyeon Kim, Jae Hyoung Cho, Byung-Wan Lee
    Journal of Korean Medical Science.2014; 29(2): 238.     CrossRef
  • Pioglitazone
    SS Jadhav, VK Shivane, AR Lila, TR Bandgar, NS Shah
    Journal of Postgraduate Medicine.2014; 60(3): 293.     CrossRef
  • Refocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes
    Hannah Seok, Bong Soo Cha
    Diabetes & Metabolism Journal.2013; 37(5): 326.     CrossRef
  • Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report
    Hirofumi Suzuki, Masaya Sakamoto, Takeshi Hayashi, Hiroyuki Iuchi, Kennosuke Ohashi, Tsuyoshi Isaka, Noriko Sakamoto, Yosuke Kayama, Katsuyoshi Tojo, Michihiro Yoshimura, Kazunori Utsunomiya
    Cardiovascular Diabetology.2013;[Epub]     CrossRef
  • The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
    Hanford Yau, Kathya Rivera, Romina Lomonaco, Kenneth Cusi
    Current Diabetes Reports.2013; 13(3): 329.     CrossRef
  • Letter: The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone (Diabetes Metab J2012;36:371-8)
    Sheyu Li, Haoming Tian
    Diabetes & Metabolism Journal.2013; 37(1): 81.     CrossRef
  • Metabolic Surgery for Type 2 Diabetes in Patients with a BMI of <35 kg/m2: A Surgeon’s Perspective
    Ricardo Cohen, Pedro Paulo Caravatto, Tarissa Petry
    Obesity Surgery.2013; 23(6): 809.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer
TOP